Bright Minds Biosciences Inc. · CSE:DRUG
Bright Minds Biosciences — Investor Presentation (September 2024)
25 slides from Bright Minds Biosciences's investor presentation, September 2024
Slide 1: Novel Drugs for Targeted Treatment of CNS & Neuropsychiatric Disorders
Novel Drugs for Targeted Treatment of CNS & Neuropsychiatric Disorders September 2024
Slide 2: Disclaimer and Cautionary Note regarding Forward Looking Statements
Disclaimer and Cautionary Note regarding Forward Looking Statements This corporate presentation (this “Presentation”) of Bright Minds Biosciences Inc. (the “Company”) is current as of September 2024, on reasonable terms; (xx) judicial proceedings, including those related to product liability; (xxi)
Slide 3: Introduction and Overview
Introduction and Overview Healing the central nervous system & brain through regulating serotonin New approaches to neuroscience create Bright Minds NASDAQ: DRUG | BRIGHTMINDSBIO.COM 3
Slide 4: Creating New Chemical Entities That Target Serotonin Agonism
Creating New Chemical Entities That Target Serotonin Agonism Serotonin (5-HT) is the most prominent neurotransmitter in the brain and modulates many functions Key 5-HT2 Receptors Targets 5-HT2A 5-HT2C Agonists 5-HT2A/2C Agonists Agonists Depression, PTSD Depression, Generalized Epilepsy, Impulsivity
Slide 5: Leadership and scientific advisors
Leadership and scientific advisors Leading experts in Epilepsy Joseph Sullivan, MD Dennis Dlugos, MD Jackie French, MD Pediatric neurologist, director of Professor of neurology and Professor of Neurology in the the UCSF Pediatric Epilepsy pediatrics at Children’s Hospital Comprehensive Epilepsy Cent
Slide 6: Pipeline
Pipeline Rich and diverse portfolio in neurology and psychiatry with multiple programs Lead Features Development Stage Indications 5-HT2C agonists for CNS disorders BMB-101 • Selective and biased 2C agonist Rare epilepsies • Biased agonism with minimal arrestin recruitment Clinical – Phase 2 • Suita
Slide 7: Epilepsy Treatment Landscape
Epilepsy Treatment Landscape Drug Resistant Epilepsies Remain Underserved
Slide 8: Drug-resistant epilepsy is still a significant issue
Drug-resistant epilepsy is still a significant issue Definition: ~30% Drug-resistant epilepsy is characterized by the persistence of Epilepsy patients develop of seizures despite the use of at least two appropriate drug resistance antiseizure medications (ASMs) at effective doses Despite the availab
Slide 9: Treatment of Drug-Resistant Epilepsies
Treatment of Drug-Resistant Epilepsies Recent drug development focused on Dravet, LGS and other DEEs Mixed Acute Seizure Therapy / Prodromes Medically Controllable Other DEE Syndromes Dravet 70% TSC Currently targeted by 5- Infant ile Spasms HT2C agonists Lennox – Gastaul Syndrome Autoi mmune epilep
Slide 10: Market potential
Market potential Projected US market Jeavons->Absence epilepsy approach Strong IP protection until EEM (Jeavons) Absence Epilepsy ~$2 Bn Peak 2041* 90 000 patients 230 000 patients revenue potential DEE approach Overcrowded drug development space *Including PTE extensions Dravet LGS CDKL5 Broad DEE
Slide 11: BMB-101
Lead Indication BMB-101 Drug-resistant epilepsies Novel 5-HT2C Selective Agonist Phase 2 Potential Indications Impulsivity Disorders Weight Management
Slide 12: BMB-101 – a next-generation 5-HT2C agonist for chronic treatment
BMB-101 – a next-generation 5-HT2C agonist for chronic treatment • Very potent and selective at 5-HT2C receptor Potency and Selectivity • No significant activity at other 5-HT receptors Safety in clinical trials • Safe and tolerable at all tested doses Phase 1 • Excellent PK/PD properties and centra
Slide 13: BMB-101 is uniquely positioned to address major unmet needs
BMB-101 is uniquely positioned to address major unmet needs Proof of mechanism Safety and PK/PD demonstrated in Ph.1 Highly selective G-protein biased properties validated in Increased gamma-power on 5-HT2C agonist agonist Phase 1 qEEG Compound 5-HT2A 5-HT2B 5-HT2C 1300 10 1200 Mean (±SD) Concentrat
Slide 14: 5-HT2C agonism provides superior efficacy in DEE epilepsies
5-HT2C agonism provides superior efficacy in DEE epilepsies 5-HT2C agonists Fenfluramine DEE - Developmental and Epileptic Encephalopathy DS – Dravet Syndrome LGS – Lennox Gastaut Syndrome TSC - Tuberous sclerosis CDD - CDKL5 deficiency disorder OLE – Open-Label Extension NASDAQ: DRUG | BRIGHTMINDSB
Slide 15: Epilepsy with Eyelid Myoclonia
Epilepsy with Eyelid Myoclonia (also known as EEM, Jeavons Syndrome) This is a rare epileptic disorder with high drug-resistance Generalized epilepsy syndrome with childhood - onset (6-8 years). Other seizure types, including absence seizures and generalized tonic-clonic seizures may be present. Som
Slide 16: BMB-101 – Novel scaffold 5-HT2C agonist
BMB-101 – Novel scaffold 5-HT2C agonist Fenfluramine/ LP352/ BMB-101 Lorcaserin Norfenfluramine Bexicaserin Lack of 5-HT2B liability ✓ ✓ x ✓ (related to cardiac toxicity) 5-HT2C Biased Agonism ✓ x x x (Sustained efficacy) No 5-HT2A Dose limiting effects ✓ x x ✓ Can be Dose-optimized ✓ x x ✓ Increase
Slide 17: Undervalued relative to rare epilepsy peers
Undervalued relative to rare epilepsy peers 1440X DRUG’s 380X 192X 280X 1440X Valuation DRUG’s Valuation DRUG’s DRUG’s Valuation Valuation DRUG’s Valuation $7.2Bn Market Cap Market Cap $5M $7.2Bn $1.9Bn $0.96Bn $1.4Bn Transaction Value $7.2Bn $1.9Bn $0.96Bn $1.4Bn M CAP $5M M CAP Epidiolex Fintepla
Slide 18: Biotech Companies in Rare CNS
Biotech Companies in Rare CNS Azetukalner/ XEN1101 3 Valuation, Focal onset seizures $ Bn 2.5 Recent deals in 2023: 2 • Karuna 14B by BMS (Multiple CNS) • Cerevel 8.7 Bn by Abbvie Bexicaserin (Schizophrenia/Epilepsy/ Parkinson’s) Ion Channels Dravet/LGS/ 1.5 Serotonin DEE Other 1 Ulixacaltamide 0.5
Slide 19: Next Generation Psychedelics
Next Generation (Candidate Profiling; IND enabling Studies Ongoing ) Psychedelics Lead Indication Depression Novel 5-HT2A | 5-HT2A/2C Agonists BMB approach to psychedelics – novel 5-HT2A agonists overview
Slide 20: Pharmacotherapy in Depression
Pharmacotherapy in Depression Psilocybin, MDMA, LSD SSRIs (1st generation psychedelics) Widely prescribed, easy to use and Infrequent dosing (e.g. 1-2 doses) demonstrate high efficacy with quick onset of cheap options with slow onset, action. Symptoms easen up for up to 12 months. limited efficacy a
Slide 21: Novel Approach to Next Generation Psychedelics
Novel Approach to Next Generation Psychedelics Key Problems with Vision/Solution for First Generation Psychedelics Next Generation Psychedelics Currently marketed drugs are active at all 5-HT receptors, including 5-HT2B, which carries cardiovascular risk and Drugs that are selective agonists for 5-H
Slide 22: Exquisite selectivity in BMB programs without 2B activity
Exquisite selectivity in BMB programs without 2B activity 1000 BMB-202 100 Log EC50 at 5-HT2C BMB-101 Psilocin BMB-201 10 Lorcaserin Norfenfluramine 1 0.1 1 10 100 1000 Log EC50 at 5-HT2A 0.1 More potent than psilocin at 2A receptor NASDAQ: DRUG | BRIGHTMINDSBIO.COM 22
Slide 23: BMB-201 and BMB-202 vs Psilocin
BMB-201 and BMB-202 vs Psilocin Psilocin BMB-201 BMB-202 5-HT2A 5-HT2B 5-HT2C Compound • No significant 5-HT2B activity EC50, nM (Emax, %) EC50, nM (Emax, %) EC50, nM (Emax, %) Psilocin 8.3 (82%) 1.1 (63%) 7.8 (95%) • BMB-201 is less potent than psilocybin/psilocin; • BMB-202 is the most selective 5
Slide 24: BMB-202 and BMB-201 – potential for best in class
BMB-202 and 201 – potential for best in class BMB-202 BMB-201 The most selective 5-HT2A agonist in Potent inducer of neuroplasticity development* Science Science ✓ Designed to have short psychoactive effects time ✓ Designed to have minimal or absent psychoactive effects ✓ ADMEPK profiling completed
Slide 25: Thank you
© BRIGHT 2’ MINDS Thank you
Bright Minds Biosciences — Investor Presentation (September 2024) on 6ix